Warning Label For Gadolinium Contrast Agents Gets US FDA Panel Backing
Executive Summary
Advisory committee agrees that risks of gadolinium retention in the brain and other organs need further study; actor Chuck Norris' wife was among several patients who testified of devastating medical problems following administration of agents.
You may also be interested in...
Opioid Litigation: Court Asks US FDA To Attend Education Session
Judge overseeing multidistrict litigation convenes meeting with senior pharma executives, government plaintiffs and others to learn about supply-chain dynamics and other issues to resolve more than 200 suits.
GBCA Sponsors Must Conduct Human, Animal Studies To Assess Safety
US FDA is requiring additional safety measures related to GBCAs, but holds that there is no direct relationship established between gadolinium retention and kidney function.
Diagnosing A Healthy US FDA: The MRI Drug Safety Review
Do MRI contrast agents cause debilitating chronic illnesses in some patients who receive them? A group of patient advocates firmly believes they do. FDA’s approach to addressing the risk via a public advisory committee shows the agency has found an effective way to handle the type of safety scare that could have paralyzed it a decade ago.